Citi raised the firm’s price target on Bio-Rad (BIO) to $450 from $400 and keeps a Buy rating on the shares. The company reported solid Q3 results, the analyst tells investors in a research note. The firm says the “clean quarter is certainly welcomed by investors after a challenging stretch of execution.”
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter